3 – In vitro Properties of the Quinolones

[1]  M. Gombert,et al.  Susceptibility of Nocardia asteroides to new quinolones and beta-lactams , 1987, Antimicrobial Agents and Chemotherapy.

[2]  D. Hooper,et al.  Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers , 1987, Antimicrobial Agents and Chemotherapy.

[3]  L. Piddock,et al.  QUINOLONE/UREIDOPENICILLIN CROSS-RESISTANCE , 1987, The Lancet.

[4]  G. Crumplin.  PLASMID-MEDIATED RESISTANCE TO NALIDIXIC ACID AND NEW 4-QUINOLONES? , 1987, The Lancet.

[5]  S. Mitsuhashi,et al.  Norfloxacin resistance in a clinical isolate of Escherichia coli , 1987, Antimicrobial Agents and Chemotherapy.

[6]  D. Sack,et al.  PLASMID-MEDIATED RESISTANCE TO NALIDIXIC ACID IN SHIGELLA DYSENTERIAE TYPE 1 , 1987, The Lancet.

[7]  M. Yeaman,et al.  In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones , 1987, Antimicrobial Agents and Chemotherapy.

[8]  R. Spencer,et al.  Comparative in-vitro activity of five fluoroquinolones against mycobacteria. , 1987, The Journal of antimicrobial chemotherapy.

[9]  F. Soriano,et al.  Activity of nine antimicrobial agents against Corynebacterium group D2 strains isolated from clinical specimens and skin , 1987, Antimicrobial Agents and Chemotherapy.

[10]  S. Mitsuhashi,et al.  Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa , 1987, Antimicrobial Agents and Chemotherapy.

[11]  P. Fernandes,et al.  The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo. , 1987, The Journal of antimicrobial chemotherapy.

[12]  D. Raoult,et al.  Susceptibility of Rickettsia conorii and R. rickettsii to pefloxacin, in vitro and in ovo. , 1987, The Journal of antimicrobial chemotherapy.

[13]  H. Neu,et al.  In-vitro activity of two new quinolone antimicrobial agents, S-25930 and S-25932 compared with that of other agents. , 1987, The Journal of antimicrobial chemotherapy.

[14]  L. Sollenberger,et al.  Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome. , 1986, The Journal of antimicrobial chemotherapy.

[15]  H. Koornhof,et al.  In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens , 1986, Antimicrobial Agents and Chemotherapy.

[16]  J. Smith.  The mode of action of 4-quinolones and possible mechanisms of resistance. , 1986, The Journal of antimicrobial chemotherapy.

[17]  S. Mitsuhashi,et al.  Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli , 1986, Antimicrobial Agents and Chemotherapy.

[18]  I. Phillips,et al.  The comparative in-vitro activity of eight newer quinolones and nalidixic acid. , 1986, The Journal of antimicrobial chemotherapy.

[19]  W. Black,et al.  In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens , 1986, Antimicrobial Agents and Chemotherapy.

[20]  F. Mégraud,et al.  Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents , 1986, Antimicrobial Agents and Chemotherapy.

[21]  S. Mitsuhashi,et al.  Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12 , 1986, Antimicrobial Agents and Chemotherapy.

[22]  K. Yamaguchi,et al.  The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. , 1986, The Journal of antimicrobial chemotherapy.

[23]  I. Phillips,et al.  The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid. , 1986, The Journal of antimicrobial chemotherapy.

[24]  H. Neu,et al.  In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents , 1986, Antimicrobial Agents and Chemotherapy.

[25]  L. Saravolatz,et al.  Activity of quinolones against Legionellaceae. , 1986, The Journal of antimicrobial chemotherapy.

[26]  J. Ariza,et al.  In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. , 1986, The Journal of antimicrobial chemotherapy.

[27]  D. Hooper,et al.  Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli , 1986, Antimicrobial Agents and Chemotherapy.

[28]  M. Gardner,et al.  Confidence intervals rather than P values: estimation rather than hypothesis testing. , 1986, British medical journal.

[29]  C. Watanakunakorn,et al.  Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens. , 1986, The Journal of infectious diseases.

[30]  M. Cynamon,et al.  Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare , 1986, Antimicrobial Agents and Chemotherapy.

[31]  M. Delmée,et al.  Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile , 1986, Antimicrobial Agents and Chemotherapy.

[32]  I. Hayakawa,et al.  Synthesis and antibacterial activities of optically active ofloxacin , 1986, Antimicrobial Agents and Chemotherapy.

[33]  A L Barry,et al.  In vitro evaluation of A-56619 and A-56620, two new quinolones , 1986, Antimicrobial Agents and Chemotherapy.

[34]  C. Mcnulty,et al.  Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents , 1985, Antimicrobial Agents and Chemotherapy.

[35]  D. Hooper,et al.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro , 1985, Antimicrobial Agents and Chemotherapy.

[36]  J. Morris,et al.  In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents , 1985, Antimicrobial Agents and Chemotherapy.

[37]  P. van der Auwera,et al.  In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam , 1985, Antimicrobial Agents and Chemotherapy.

[38]  I. Phillips,et al.  The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin. , 1985, The Journal of antimicrobial chemotherapy.

[39]  H. Goossens,et al.  Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens , 1985, Antimicrobial Agents and Chemotherapy.

[40]  E. Perea,et al.  Activities of new quinoline derivatives against genital pathogens , 1985, Antimicrobial Agents and Chemotherapy.

[41]  R. Goering,et al.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes , 1984, Antimicrobial Agents and Chemotherapy.

[42]  S. Richmond,et al.  Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence , 1984, Antimicrobial Agents and Chemotherapy.

[43]  D. R. Deyoung,et al.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii , 1984, Antimicrobial Agents and Chemotherapy.

[44]  D. Reeves,et al.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound. , 1984, The Journal of antimicrobial chemotherapy.

[45]  I. Phillips,et al.  The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. , 1984, The Journal of antimicrobial chemotherapy.

[46]  R. Wise,et al.  In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. , 1984, The Journal of antimicrobial chemotherapy.

[47]  H. Muytjens,et al.  In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis , 1984, Antimicrobial Agents and Chemotherapy.

[48]  H. Katae,et al.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid , 1983, Antimicrobial Agents and Chemotherapy.

[49]  Y. Osada,et al.  Antimycoplasmal activity of ofloxacin (DL-8280) , 1983, Antimicrobial Agents and Chemotherapy.

[50]  I. Phillips,et al.  In vitro antibacterial activity of norfloxacin (MK-0366) , 1982, Antimicrobial Agents and Chemotherapy.

[51]  Glatt Mm,et al.  Letter: Scientific medicine. , 1974 .

[52]  I. Phillips,et al.  Comparative activity of the 4-quinolones. , 1988, Reviews of infectious diseases.

[53]  R. Spencer,et al.  In-vitro selection of bacteria resistant to the 4-quinolone agents. , 1987, The Journal of antimicrobial chemotherapy.

[54]  I. Phillips,et al.  The comparative in-vitro activity of pefloxacin. , 1986, The Journal of antimicrobial chemotherapy.

[55]  R. Auckenthaler,et al.  In-vitro activity of newer quinolones against aerobic bacteria. , 1986, The Journal of antimicrobial chemotherapy.

[56]  J. Williams,et al.  Frequency of appearance of resistant variants to norfloxacin and nalidixic acid. , 1984, The Journal of antimicrobial chemotherapy.